Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-01-18
1998-04-07
McKane, Joseph
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514361, 514381, 548129, 548132, 548253, 548254, A61K 3141, C07D27106
Patent
active
057365610
ABSTRACT:
This invention relates to a method for the prophylaxis or treatment of vascular hypertropy in a mammal by administering a pharmaceutically effective amount of a compound represented by the formula (I): ##STR1## wherein ring W is a nitrogen-containing heterocyclic ring residue which may be substituted; R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which optionally binds through a hetero-atom; R.sup.3 represents a group capable of forming an anion or a group capable of changing thereto; X shows that the phenylene and phenyl groups bind to each other directly or through a spacer having an atomic length of two or less; n denotes 1 or 2; a and b forming the heterocyclic ring residue are independently one or two optionally substituted carbon or hetero atoms; c is an optionally substituted carbon or hetero atom; provided that, when the ring W is a condensed ring, R.sup.1 is hydrogen or an optionally substituted hydrocarbon residue which binds through a hetero atom, or a salt thereof to a mammal in need thereof.
REFERENCES:
patent: 5128356 (1992-07-01), Naka et al.
patent: 5162326 (1992-11-01), Naka et al.
patent: 5166143 (1992-11-01), Ondetti et al.
patent: 5183899 (1993-02-01), Naka et al.
patent: 5210211 (1993-05-01), Hodges et al.
patent: 5243054 (1993-09-01), Naka et al.
patent: 5250554 (1993-10-01), Naka et al.
patent: 5284661 (1994-02-01), Morimoto et al.
patent: 5328919 (1994-07-01), Naka et al.
Linz et al., Molecular and Cellular Biochemistry, vol. 147, pp. 89-97, 1995.
Stedman's Medical Dictionary, 25th Edition, pp. 744, 746, and 747, 1991.
Kawamura et al., "TCV-116, A Novel Angiotensin II Receptor Antagonist, Prevents Intimal Thickening And Impairment of Vascular Function After Carotid Injury in Rats", The Journal of Pharmacology and Experimental Therapeutics, vol. 266, No. 3, pp. 1664-1669, (1993).
Yokohama, The Japanese Journal of Pharmacology, vol. 61, pp. 115P, (1993).
Azuma et al., "Prevention of Intimal Thickening After Endothelial Removal by a Nonpeptide Angiotensin II Receptor Antagonist, Losartan", british journal of Pharmacology, vol. 106, No. 3, pp. 665-671, (1992).
Prescott et al., "Angiotensin-Converting Enzyme Inhibitor Versus Angiotensin II, AT, Receptor Antagonist", The American Journal of Pathology, vol. 139, No. 6, pp. 1291-1296, (1991).
Osterrieder et al., "Role of Angiotensin II in Injury-Induced Neointima Formation in Rats", Hypertension, vol. 18, no. S1, pp. II-60-II-64, (1991).
Mizuno et al., "Hypotensive Activity of TCV-116, A Newly Developed angiotensin II Receptor Antagonist, In Spontaneously Hypertensive Rates", Life Sciences, vol. 51, pp. PL 183-187, (1992).
McKane Joseph
Takeda Chemical Industries Ltd.
LandOfFree
Vascular hypertrophy suppressor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vascular hypertrophy suppressor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vascular hypertrophy suppressor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-14027